D.Th. Sleijfer

3.0k total citations
74 papers, 2.1k citations indexed

About

D.Th. Sleijfer is a scholar working on Surgery, Oncology and Reproductive Medicine. According to data from OpenAlex, D.Th. Sleijfer has authored 74 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Surgery, 24 papers in Oncology and 15 papers in Reproductive Medicine. Recurrent topics in D.Th. Sleijfer's work include Testicular diseases and treatments (29 papers), Ovarian cancer diagnosis and treatment (10 papers) and Chemotherapy-induced organ toxicity mitigation (8 papers). D.Th. Sleijfer is often cited by papers focused on Testicular diseases and treatments (29 papers), Ovarian cancer diagnosis and treatment (10 papers) and Chemotherapy-induced organ toxicity mitigation (8 papers). D.Th. Sleijfer collaborates with scholars based in Netherlands, United Kingdom and United States. D.Th. Sleijfer's co-authors include Elisabeth G.E. de Vries, H. Schraffordt Koops, Nanno H. Mulder, Pax H.B. Willemse, Jourik A. Gietema, Harm Hoekstra, Winette T.A. van der Graaf, NH Mulder, N. H. Mulder and Heimen Schraffordt Koops and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

D.Th. Sleijfer

72 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
D.Th. Sleijfer Netherlands 28 893 687 550 401 339 74 2.1k
S.J. Harland United Kingdom 21 859 1.0× 664 1.0× 511 0.9× 225 0.6× 668 2.0× 39 2.2k
Steen Werner Hansen Denmark 20 2.0k 2.3× 993 1.4× 641 1.2× 419 1.0× 583 1.7× 45 3.1k
Kurt Brunner Switzerland 23 504 0.6× 818 1.2× 353 0.6× 171 0.4× 452 1.3× 82 1.7k
M. Gore United Kingdom 29 448 0.5× 1.1k 1.6× 816 1.5× 503 1.3× 609 1.8× 94 2.4k
L H Einhorn United States 21 875 1.0× 1.5k 2.1× 666 1.2× 348 0.9× 1.3k 3.8× 31 2.7k
P. Fargeot France 30 564 0.6× 1.7k 2.5× 355 0.6× 126 0.3× 575 1.7× 87 2.7k
Solomon Zimm United States 19 324 0.4× 580 0.8× 299 0.5× 198 0.5× 613 1.8× 30 1.8k
P.H.B. Willemse Netherlands 22 391 0.4× 486 0.7× 339 0.6× 467 1.2× 204 0.6× 62 1.4k
Gunter Deppe United States 27 845 0.9× 622 0.9× 303 0.6× 941 2.3× 318 0.9× 137 2.5k
George Omura United States 18 591 0.7× 619 0.9× 532 1.0× 832 2.1× 234 0.7× 52 2.5k

Countries citing papers authored by D.Th. Sleijfer

Since Specialization
Citations

This map shows the geographic impact of D.Th. Sleijfer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D.Th. Sleijfer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D.Th. Sleijfer more than expected).

Fields of papers citing papers by D.Th. Sleijfer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D.Th. Sleijfer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D.Th. Sleijfer. The network helps show where D.Th. Sleijfer may publish in the future.

Co-authorship network of co-authors of D.Th. Sleijfer

This figure shows the co-authorship network connecting the top 25 collaborators of D.Th. Sleijfer. A scholar is included among the top collaborators of D.Th. Sleijfer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D.Th. Sleijfer. D.Th. Sleijfer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Haas, De, Renske Altena, H.M. Boezen, et al.. (2012). Early development of the metabolic syndrome after chemotherapy for testicular cancer. Annals of Oncology. 24(3). 749–755. 75 indexed citations
2.
Holzik, Martijn F. Lutke, et al.. (2004). Genetic predisposition to testicular germ-cell tumours. The Lancet Oncology. 5(6). 363–371. 57 indexed citations
3.
Kramer, Henk, et al.. (2004). Endoscopic ultrasound-guided fine-needle aspiration in patients with mediastinal abnormalities and previous extrathoracic malignancy. European Journal of Cancer. 40(4). 559–562. 27 indexed citations
4.
Meinardi, M.T., et al.. (2002). CORRECTION. Heart. 88(1). 82–82. 3 indexed citations
5.
Sleijfer, D.Th., et al.. (2001). Completing logbooks: when and how. Medical Teacher. 23(3). 315–315.
6.
Smit, Egbert F., et al.. (2001). Dose-finding and pharmacological study of ifosfamide in combination with paclitaxel and carboplatin in resistant small-cell lung cancer. Annals of Oncology. 12(6). 787–792. 3 indexed citations
7.
Wit, Ronald de, Laurence Collette, Richard Sylvester, et al.. (1998). Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance. British Journal of Cancer. 78(10). 1350–1355. 26 indexed citations
8.
Kroesen, Bart‐Jan, D.Th. Sleijfer, Grietje Molema, et al.. (1997). Approaches to lung cancer treatment using the CD3E×GP-2-directed Bispecific Monoclonal Antibody BIS-1. Cancer Immunology Immunotherapy. 45(3-4). 203–206. 27 indexed citations
9.
Basten, J.P. van, Mels F. van Driel, Grieteke Jonker-Pool, et al.. (1997). Sexual functioning in testosterone‐supplemented patients treated for bilateral testicular cancer. British Journal of Urology. 79(3). 461–467. 17 indexed citations
10.
Basten, J.P. van, Heimen Schraffordt Koops, D.Th. Sleijfer, et al.. (1997). Current concepts about testicular cancer. European Journal of Surgical Oncology. 23(4). 354–360. 46 indexed citations
11.
Basten, J.P. van, Harm Hoekstra, Mels F. van Driel, et al.. (1997). Sexual dysfunction in nonseminoma testicular cancer patients is related to chemotherapy-induced angiopathy.. Journal of Clinical Oncology. 15(6). 2442–2448. 34 indexed citations
12.
Sleijfer, D.Th., et al.. (1996). Outpatient-based Subcutaneous Interleukin-2 Monotherapy in Advanced Renal Cell Carcinoma: an Update. Cancer Biotherapy and Radiopharmaceuticals. 11(5). 289–295. 4 indexed citations
13.
Janssen, René A. J., Jan Buter, G Mesander, et al.. (1995). Immunomodulatory effects of intravenous BIS-1 F(ab')2 administration in renal cell cancer patients. British Journal of Cancer. 72(3). 795–799. 10 indexed citations
14.
Kroesen, Bart‐Jan, René A. J. Janssen, Jan Buter, et al.. (1995). Bispecific Monoclonal Antibodies for Intravenous Treatment of Carcinoma Patients: Immunobiologic Aspects. Journal of Hematotherapy. 4(5). 409–414. 9 indexed citations
15.
Gietema, Jourik A., G.J. Veldhuis, Henk‐Jan Guchelaar, et al.. (1995). Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer. British Journal of Cancer. 71(6). 1302–1307. 44 indexed citations
16.
Mulder, NH, et al.. (1994). Dacarbazine (DTIC)-based chemotherapy or chemoimmunotherapy of patients with disseminated malignant melanoma. British Journal of Cancer. 70(4). 681–683. 13 indexed citations
17.
Gietema, Jourik A., D.Th. Sleijfer, H. Schraffordt Koops, et al.. (1992). Long-term Follow-up of Cardiovascular Risk Factors in Patients Given Chemotherapy for Disseminated Nonseminomatous Testicular Cancer. Annals of Internal Medicine. 116(9). 709–715. 73 indexed citations
18.
Gietema, Jourik A., et al.. (1991). Alternating cycles of PVB and BEP in the treatment of patients with advanced seminoma. European Journal of Cancer and Clinical Oncology. 27(11). 1376–1379. 6 indexed citations
19.
Vries, Elisabeth G.E. de, J. W. Greidanus, Nanno H. Mulder, et al.. (1987). A phase I and pharmacokinetic study with 21-day continuous infusion of epirubicin.. Journal of Clinical Oncology. 5(9). 1445–1451. 23 indexed citations
20.
Vries, Elisabeth G.E. de, et al.. (1984). No narcosis for bone marrow harvest in autologous bone marrow transplantation. Annals of Hematology. 49(5). 419–421. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by S.J. Harland Breakdown of academic impact, for papers by Steen Werner Hansen Breakdown of academic impact, for papers by Kurt Brunner Breakdown of academic impact, for papers by M. Gore Breakdown of academic impact, for papers by L H Einhorn Breakdown of academic impact, for papers by P. Fargeot Breakdown of academic impact, for papers by Solomon Zimm Breakdown of academic impact, for papers by P.H.B. Willemse Breakdown of academic impact, for papers by Gunter Deppe Breakdown of academic impact, for papers by George Omura
Rankless by CCL
2026